Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00942981
Recruitment Status : Recruiting
First Posted : July 21, 2009
Last Update Posted : December 20, 2018
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:


  • Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions.
  • The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people who have dopamine disorders (such as schizophrenia) and those who do not. Researchers are interested in studying the dopamine system to gain a better idea of how dopamine disorders develop, which may lead to better medical care for people with schizophrenia.


- To study the amount and distribution of two types of dopamine receptors.


  • Individuals between the ages of 18 and 60 who have schizophrenia.
  • Healthy volunteers between the ages of 18 and 90.


  • Participants will undergo a full screening, with physical and psychological history, a neurological examination, and blood and urine samples.
  • Participants will have a blood flow map of the brain recorded with a positron emission tomography (PET) brain scan. A magnetic resonance imaging (MRI) scan will also be performed to determine brain anatomy.
  • To study the amount and distribution of dopamine receptors in the brain, participants will receive a small amount of a radioactive chemical in the vein, followed by a PET scan.
  • The procedure will be performed twice in two separate sessions, once for [18F]fallypride and once for [11C]NNC-112.

Condition or disease
Schizoaffective Disorder Schizophrenia

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 330 participants
Time Perspective: Other
Official Title: Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
Study Start Date : July 17, 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. Regional binding potentials of [11C]NNC-112 and [18F]Fallypride

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  • Subjects will be recruited among individuals volunteering for NIH protocol 95-M-0150 A Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings (PI: Daniel Weinberger, M.D.), NIH protocol 00-M-0085 Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers with 3.0 Tesla MRI and Magnetoencephalography. (P.I.: Venkata Mattay, MD) or NIH protocol 89-M-0160 Inpatient Evaluation of Neuropsychiatric Patients (PI: Jose Apud, M.D. Ph.D).
  • Only adult subjects who are able to provide informed consent will be studied.
  • Patients will be between 18 and 60 years of age. Healthy controls will be matched by age and sex to the patients.
  • Control subjects must be healthy based on history, laboratory and physical exam obtained through the above mentioned protocols and will be included up to the age of 90 years.

EXCLUSION CRITERIA: (for patients and controls except where indicated)

  • Subjects will be excluded if they don t fit the study requirements regarding age, ability to provide informed consent, absence of significant general medical, neurological or psychiatric disorders (except the disorder object of study), or intake of substances that interfere with central dopaminergic signaling.
  • Pregnant or breast feeding.
  • Current psychiatric illness except for patients with schizophrenia, schizoaffective disorder or other psychotic disorder
  • Current or prior use (within 4 weeks) of substances that interfere with central dopaminergic signaling (e.g. antipsychotics, dopamine receptor agonists, anticholinergics, MAO-B inhibitors)
  • History of any (excepting nicotine- related) DSM5-defined substance dependence).
  • Cumulative lifetime history of any (excepting nicotine -related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse
  • Controls with current psychiatric illness other than schizophrenia, schizoaffective disorder, or other psychotic disorder
  • Secondary causes of schizophrenia-like syndromes, e.g. amphetamine abuse, brain infarction, tumor, or trauma
  • Neurological disorders except those of exclusively peripheral location
  • Significant prior or current substance abuse, severe systemic disease, hypothyroidism not compensated by medication
  • Laboratory tests with clinically significant abnormalities
  • History of a significantly abnormal EEG, cranial CT or MRI
  • Conditions that increase risk for MRI (pacemaker devices, ferromagnetic metal implants, etc.)
  • Prior participation in other research protocols such that radiation exposure would exceed the annual NIH RSC limits
  • Any medical condition that, in the opinion of the investigators, would interfere with the safe conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00942981

Contact: Jasmin Czarapata, Ph.D. (301) 435-7645
Contact: Karen F Berman, M.D. (301) 496-7603

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Principal Investigator: Karen F Berman, M.D. National Institute of Mental Health (NIMH)

Additional Information:
Publications: Identifier: NCT00942981     History of Changes
Other Study ID Numbers: 090176
First Posted: July 21, 2009    Key Record Dates
Last Update Posted: December 20, 2018
Last Verified: December 4, 2018

Studies a U.S. FDA-regulated Drug Product: No

Keywords provided by National Institutes of Health Clinical Center (CC):
PET Study
(18F) Fallypride
Schizoaffective Disorder
Healthy Volunteer

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents